Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities

Digestion ◽  
2018 ◽  
Vol 99 (4) ◽  
pp. 283-292 ◽  
Author(s):  
Hiroshi Yamawaki ◽  
Seiji Futagami ◽  
Keiko Kaneko ◽  
Shuhei Agawa ◽  
Kazutoshi Higuchi ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Combination Therapy ◽  
Functional Dyspepsia ◽  
Epigastric Pain ◽  
Pancreatic Enzyme ◽  
Camostat Mesilate

scholarly journals Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography

2017 ◽  
Vol 61 (2) ◽  
pp. 140-145 ◽  
Author(s):  
Satomi Hashimoto ◽  
Seiji Futagami ◽  
Hiroshi Yamawaki ◽  
Keiko Kaneko ◽  
Yasuhiro Kodaka ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Epigastric Pain ◽  
Pancreatic Enzyme ◽  
Pain Syndrome ◽  
Epigastric Pain Syndrome

scholarly journals Pancreatic Fibrosis (Early Chronic Pancreatitis) as Emerging Diagnosis in Structural Causes of Dyspepsia: Evidence from Endoscopic Ultrasonography and Shear Wave Elastography

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1252
Author(s):  
Chung-Tsui Huang ◽  
Tzong-Hsi Lee ◽  
Cheng-Kuan Lin ◽  
Chao-Yi Chen ◽  
Yi-Feng Yang ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Chronic Pancreatitis ◽  
Gastric Emptying ◽  
Peptic Ulcer Disease ◽  
Functional Dyspepsia ◽  
Chromogranin A ◽  
Pancreatic Enzyme ◽  
Pancreatic Fibrosis ◽  
Ulcer Disease

A new concept for the diagnosis and management of non-functional dyspepsia in guidelines was lacking in the past decade. Medical advancement has proven pancreatic fibrosis (essential image evidence of early chronic pancreatitis) to be a cause of dyspepsia and related to pancreatic exocrine dysfunction. This study aimed to analyze the clinical picture, biomarker, and percentage of pancreatic fibrosis in the dyspeptic population. A total of 141 consecutive patients were retrospectively enrolled. They were diagnosed with peptic ulcer disease, 9.2% (n = 13); pancreatic fibrosis, 17% (n = 24); pure Helicobacter pylori infection, 19.9% (n = 28); functional dyspepsia, 53.2% (n = 75); and chronic pancreatitis, 0.7% (n = 1). Among those with pancreatic fibrosis, (n = 24), 11 were diagnosed on the basis of a pancreatic acoustic radiation force impulse exceeding 1.4 m/s, and the remaining 13 were diagnosed with early chronic pancreatitis with at least three of the Japanese endoscopic ultrasonography criteria. The anatomic distribution of parenchymal criteria of early chronic pancreatitis was head, 53%; body, 38%; and tail, 9%. There were 17 cases (71%, 17/24) without Helicobacter pylori and whose dyspepsia improved after pancreatic enzyme replacement with a ratio of 82.3% (14/17). Of the 141 cases, 19 received gastric emptying scintigraphy and Western blot analysis of chromogranin-A in duodenal mucosa. Delayed gastric emptying was more common in functional dyspepsia and chromogranin-A was expressed more in pancreatic fibrosis. In conclusion, pancreatic fibrosis (including early chronic pancreatitis) outnumbered peptic ulcer disease in the dyspeptic population and pancreatic enzyme therapy was effective for 82% of cases. In early chronic pancreatitis, pancreatic fibrosis is dominant in the head location, and duodenum mucosa chromogranin-A is a potential biomarker with increased expression in an age-matched manner.

Carnitine profile in pancreatic enzyme supplemented patients with chronic pancreatitis

2007 ◽  
Vol 45 (05) ◽  
Author(s):  
M Figler ◽  
CG Talián ◽  
J Bene ◽  
J Cseh ◽  
I Battyány ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Pancreatic Enzyme

scholarly journals Comparison of clinical symptoms, gastric motility and fat intake in the early chronic pancreatitis patients with anti-acid therapy-resistant functional dyspepsia patients

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0205165 ◽  
Author(s):  
Mako Wakabayashi ◽  
Seiji Futagami ◽  
Hiroshi Yamawaki ◽  
Atsushi Tatsuguchi ◽  
Keiko Kaneko ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Functional Dyspepsia ◽  
Gastric Motility ◽  
Clinical Symptoms ◽  
Fat Intake ◽  
Acid Therapy

scholarly journals DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia

2018 ◽  
Vol 19 (12) ◽  
pp. 4035 ◽  
Author(s):  
Mirim Jin ◽  
Miwon Son
Keyword(s):  
Functional Dyspepsia ◽  
Serotonin Receptors ◽  
Epigastric Pain ◽  
Herbal Medicines ◽  
Gastrointestinal Disorder ◽  
Clinical Results ◽  
Promising Alternative ◽  
Postprandial Fullness ◽  
Botanical Drug ◽  
Upper Abdomen

Functional dyspepsia (FD) is the most common functional gastrointestinal disorder (FGID). FD is characterized by bothersome symptoms such as postprandial fullness, early satiety, and epigastric pain or burning sensations in the upper abdomen. The complexity and heterogeneity of FD pathophysiology, which involves multiple mechanisms, make both treatment and new drug development for FD difficult. Current medicines for FD targeting a single pathway have failed to show satisfactory efficacy and safety. On the other hand, multicomponent herbal medicines that act on multiple targets may be a promising alternative treatment for FD. DA-9701 (Motilitone), a botanical drug consisting of Corydalis Tuber and Pharbitidis Semen, has been prescribed for FD since it was launched in Korea in 2011. It has multiple mechanisms of action such as prokinetic effects, fundus relaxation, and visceral analgesia, which are mediated by dopamine D2 and several serotonin receptors involved in gastrointestinal (GI) functions. In clinical studies, DA-9701 has been found to be beneficial for improvement of FD symptoms and GI functions in FD patients, while showing better safety compared to that associated with conventional medicines. In this review, we provide updated information on the pharmacological effects, safety, and clinical results of DA-9701 for the treatment of FGIDs.

scholarly journals A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride in Functional Dyspepsia

2020 ◽  
Vol 5 (2) ◽  
pp. 50-56
Author(s):  
Ganesh Narain Saxena ◽  
Saumya Mathur
Keyword(s):  
Functional Dyspepsia ◽  
Safety Profile ◽  
Epigastric Pain ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Early Satiety ◽  
Postprandial Fullness ◽  
Presenting Symptoms ◽  
Randomized Controlled

ABSTRACT Introduction Dyspepsia is a clinical problem of considerable magnitude for the healthcare system due to the high prevalence and chronic and recurrent nature of symptoms. Earlier dyspepsia was referred to as a heterogeneous group of symptoms in the upper abdomen and retrosternal which are related to ingestion of meals and include heartburn, regurgitation, epigastric pain, epigastric burning, postprandial fullness/distension, early satiety, bloating, belching, anorexia, nausea, and vomiting. This has prompted the search for newer agents with equal efficacy but lower side effect potential such as levosulpiride and itopride. Aim and objectives To evaluate and compare the efficacy of the newer drugs like levosulpiride and itopride in functional dyspepsia. Observations and results The most common presenting symptoms in the present study were epigastric fullness (81%), upper abdominal pain (55%), early satiety (52%), and epigastric burning (45%). Less common symptoms were bloating (27%), belching (11%), heartburn (10%), and nausea (8%). Conclusion Drugs, itopride and levosulpiride, were equally effective in ameliorating different symptoms of functional dyspepsia at the end of 4 weeks of treatment. There was a significant reduction in mean global symptom score (GSS) and mean duration score and mean score of severity in follow-up visits at the 2nd and 4th week from the day of presentation (p value < 0.05). How to cite this article Saxena GN, Mathur S. A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride in Functional Dyspepsia. J Mahatma Gandhi Univ Med Sci Tech 2020;5(2):50–56.

Variations in time of serum pancreatic enzyme levels in chronic pancreatitis and clinical course of the disease

1991 ◽  
Vol 8 (4) ◽  
Author(s):  
Luigi Benini ◽  
Silvio Caliari ◽  
Bruna Vaona ◽  
Giorgio Brocco ◽  
Rocco Micciolo ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Clinical Course ◽  
Pancreatic Enzyme
Sign in / Sign up

Export Citation Format

Share Document